VisionGate founder, chairman and CEO Dr. Alan Nelson explains to Mike Ward, Informa Pharma Insights global director of content, what has motivated the company to migrate from being a diagnostics business to one having a therapeutics focus. Having developed a non-invasive test for lung cancer, LuCED, which also has indicated an ability to detect various tumor types and stages of lung cancer, including Stage I and even dysplasia, VisionGate acquired exclusive rights to the University of Colorado’s patent for the use of the drug Iloprost, a drug currently used to treat various lung diseases such as pulmonary arterial hypertension, in the prevention of lung cancer. Dr. Nelson details how the company and the University of Colorado will conduct a Phase IIB validation trial where LuCED is compared with biopsy, leading to the Phase III trial in dysplasia.
Find more videos and articles at [ Ссылка ]
For more information on Biotech Showcase™, visit our webpage: [ Ссылка ]
